Molecure S.A. (WSE: MOC) is a clinical-stage Polish biotechnology firm focused on small molecule therapies targeting unexplored protein and RNA targets. With a proprietary discovery engine and strategic partnerships, including with global pharma, Molecure is advancing programs in oncology, immunology, and respiratory diseases. The company combines internal R&D with open innovation to accelerate drug development. It offers investors high-risk, high-reward exposure to first-in-class therapeutics emerging from European biotech research.
差价合约 (CFD) 是一种复杂的金融工具，利用杠杆交易虽然可能放大收益，但同样也会加剧亏损风险，导致资金快速流失。数据显示，82.78% 的散户投资者在使用该提供商服务进行差价合约交易时出现账户亏损。在进行交易之前，请确保您充分了解差价合约的运作机制，并仔细评估自己是否有能力承担资金亏损的高风险。
评分与评论
评分与评论
